Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Strahlentherapie und Onkologie
Erschienen in:

11.08.2023 | Original Article

Utility of pre-chemoradiotherapy Pan-Immune-Inflammation-Value for predicting the osteoradionecrosis rates in locally advanced nasopharyngeal cancers

verfasst von: Busra Yilmaz, Efsun Somay, Erkan Topkan, Ahmet Kucuk, Berrin Pehlivan, Ugur Selek

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this retrospective study was to explore whether pretreatment Pan-Immune-Inflammation-Value (PIV) measurements might predict the risk of mandibular osteoradionecrosis (ORN) in patients receiving concurrent chemoradiotherapy (CCRT) for locally advanced nasopharyngeal cancer (LA-NPC).

Methods

The platelet, monocyte, neutrophil, and lymphocyte counts acquired on the first day of CCRT were used to compute pretreatment PIV levels: PIV = (Platelets × Monocytes × Neutrophils) ÷ Lymphocytes. Receiver operating characteristic curve analysis was used to determine the association between ORN rates and PIV levels. Spearman correlation analysis was used to examine the probable intergroup correlations. The potential link between the pretreatment PIV levels and the post-treatment ORN rates was determined as the primary objective.

Results

21 (10.0%) of 210 eligible patients were diagnosed with ORN. The optimal pre-CCRT PIV cutoff was 833, which separated patients into two PIV groups with divergent ORN prevalence estimates: Group 1: PIV < 833 (N = 153), and Group 2: PIV ≥ 833 (N = 57). The comparison analysis found that the PIV ≥ 833 cohort had significantly higher ORN rates than the PIV < 833 cohort (29.8% vs. 2.6%; P < 0.001). Other characteristics linked to significantly higher ORN rates were the patient’s continuing smoking, the use of the Three-dimensional conformal radiation therapy technique, the mean mandibular dose of ≥ 58.1 Gy, the number of tooth extractions before CCRT ≥ 4, and the presence of tooth extractions after CCRT. The independent importance of all factors on higher ORN occurrence rates were retained in multivariate analysis (P < 0.05).

Conclusions

Our findings revealed a strong link between aggravated inflammatory response and ORN genesis, with high pretreatment PIV levels related to significantly higher ORN rates.
Literatur
1.
Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMed
2.
de Felice F, de Vincentiis M, Luzzi V, Magliulo G, Tombolini M, Ruoppolo G et al (2018) Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management. Oral Oncol 77:125–130PubMed
3.
Bras J, de Jonge HK, van Merkesteyn JP (1990) Osteoradionecrosis of the mandible: pathogenesis. Am J Otolaryngol 11:244–250PubMed
4.
Ben-David MA, Diamante M, Radawski JD, Vineberg KA, Stroup C, Murdoch-Kinch CA et al (2007) Lack of osteoradionecrosis of the mandible after IMRT for head and neck cancer: likely contributions of both dental care and improved dose distribution. Int J Radiat Oncol Biol Phys 68:392–402
5.
Beumer J, Harrison R, Sanders B, Kurrasch M (1983) Postradiation dental extractions: a review of the literature and a report of 72 episodes. Head Neck Surg 6:581–586PubMed
6.
Jawad H, Hodson NA, Nixon PJ (2015) A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: part 1. Br Dent J 218:65–68PubMed
7.
Jawad H, Hodson NA, Nixon PJ (2015) A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: part 2. Br Dent J 218:69–74PubMed
8.
Chrcanovic BR, Albrektsson T, Wennerberg A (2016) Dental implants in irradiated versus nonirradiated patients: a meta-analysis. Head Neck 38:448–441PubMed
9.
Buglione M, Cavagnini R, Di Rosario F, Sottocornola L, Maddalo M, Vassalli L et al (2016) Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: dental pathologies and osteoradionecrosis (part 1) literature review and consensus statement. Crit Rev Oncol Hematol 97:131–142PubMed
10.
Caparrotti F, Huang SH, Lu L, Bratman SV, Ringash J, Bayley A et al (2017) Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. Cancer 123:3691–3700PubMed
11.
Oh HK, Chambers MS, Garden AS, Wong PF, Martin JW (2004) Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. J Oral Maxillofac Surg 62:139–144PubMed
12.
Costantino PD, Friedman CD, Steinberg MJ (1995) Irradiated bone and its management. Otolaryngol Clin North Am 28:1021–1038PubMed
13.
Marx RE (1983) Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 41:283–288PubMed
14.
Xu J, Zheng Z, Fang D, Gao R, Liu Y, Fan ZP et al (2012) Early-stage pathogenic sequence of jaw osteoradionecrosis in vivo. J Dent Res 91:702–708PubMed
15.
Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482–2494PubMed
16.
Woollard KJ, Geissmann F (2010) Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 7:77–86PubMedPubMedCentral
17.
Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O et al (2011) Low lymphocyte count and cardiovascular diseases. Curr Med Chem 18:3226–3233PubMed
18.
Prabhu SD, Frangogiannis NG (2016) The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res 119:91–112PubMedPubMedCentral
19.
Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159–175PubMed
20.
Zhang J, Lu X, Wang S, Li H (2021) High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with poor survival in patients with hemodialysis. Biomed Res Int 2021:9958081PubMedPubMedCentral
21.
Somay E, Yilmaz B (2021) High pretreatment systemic immune-inflammation index values are associated with diminished short-term success after temporomandibular joint arthrocentesis procedure. BMC Oral Health 21:531PubMedPubMedCentral
22.
Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S et al (2020) The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials. Br J Cancer 123:403–409PubMedPubMedCentral
23.
Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R et al (2021) The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers (Basel) 13:1964PubMed
24.
Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C et al (2021) The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer 150:155–167PubMed
25.
Fucà G, Beninato T, Bini M, Mazzeo L, di Guardo L, Cimminiello C et al (2021) The Pan-Immune-Inflammation Value in patients with metastatic melanoma receiving first-line therapy. Target Oncol 16:529–536PubMed
26.
Zeng R, Liu F, Fang C, Yang J, Luo L, Yue P et al (2021) PIV and PILE score at baseline predict clinical outcome of anti-pd-1/pd-l1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients. Front Immunol 12:724443PubMedPubMedCentral
27.
Gambichler T, Hessam S, Cramer P, Abu Rached N, Bechara FG (2022) Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 36(9):1593–1596PubMed
28.
White SC, Pharoah MJ (2018) Oral radiology-E-book: principles and interpretation. Elsevier, St. Louis, pp 808–832
29.
Yilmaz B, Somay E, Selek U, Topkan E (2021) Pretreatment systemic immune-inflammation index predict needs for teeth extractions for locally advanced head and neck cancer patients undergoing concurrent chemoradiotherapy. Ther Clin Risk Manag 17:1113–1121PubMedPubMedCentral
30.
Notani K, Yamazaki Y, Kitada H, Sakakibara N, Fukuda H, Omori K et al (2003) Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck 25:181–186PubMed
31.
Chrcanovic BR, Reher P, Sousa AA, Harris M (2010) Osteoradionecrosis of the jaws—a current overview—part 1: physiopathology and risk and predisposing factors. Oral Maxillofac Surg 14:3–16PubMed
32.
Dhanda J, Pasquier D, Newman L, Shaw R (2016) Current concepts in osteoradionecrosis after head and neck radiotherapy. Clin Oncol 28:459–466
33.
Sohn HO, Park EY, Jung YS, Lee JY, Kim EK (2021) Effects of the professional oral care management program on patients with head and neck cancer after radiotherapy: a 12-month follow-up. J Dent Sci 16:453–459PubMed
34.
Moon DH, Moon SH, Wang K, Weissler MC, Hackman TG, Zanation AM et al (2017) Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncol 72:98–103PubMed
35.
Owosho AA, Tsai CJ, Lee RS, Freymiller H, Kadempour A, Varthis S et al (2017) The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): the memorial Sloan Kettering cancer center experience. Oral Oncol 64:44–51PubMed
36.
Aarup-Kristensen S, Hansen CR, Forner L, Brink C, Eriksen JG, Johansen J (2019) Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations. Acta Oncol 58:1373–1377PubMed
37.
Beech NM, Porceddu S, Batstone MD (2017) Radiotherapy-associated dental extractions and osteoradionecrosis. Head Neck 39:128–132PubMed
38.
Balermpas P, van Timmeren JE, Knierim DJ, Guckenberger M, Ciernik IF (2022) Dental extraction, intensity-modulated radiotherapy of head and neck cancer, and osteoradionecrosis: a systematic review and meta-analysis. Strahlenther Onkol 198:219–228PubMedPubMedCentral
39.
Kowolik MJ, Dowsett SA, Rodriguez J, Eckert GJ, de la Rosa RM (2001) Systemic neutrophil response resulting from dental plaque accumulation. J Periodontol 72:146–151PubMed
40.
Acharya AB, Shetty IP, Jain S, Padakannaya I, Acharya S, Shettar L et al (2019) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic periodontitis before and after nonsurgical therapy. J Indian Soc Periodontol 23:419–423PubMedPubMedCentral
41.
Tulgar YK, Cakar S, Tulgar S, Dalkilic O, Cakiroglu B, Uyanik BS (2016) The effect of smoking on neutrophil/lymphocyte and platelet/lymphocyte ratio and platelet ındices: a retrospective study. Eur Rev Med Pharmacol Sci 20:3112–3118PubMed
42.
Anandha Lakshmi S, Lakshmanan A, Ganesh Kumar P, Saravanan A (2014) Effect of intensity of cigarette smoking on haematological and lipid parameters. J Clin Diagn Res 8:BC11–BC13
43.
Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMed
44.
Szydełko J, Litwińczuk M, Szydełko M, Matyjaszek-Matuszek B (2020) Neutrophil-to-lymphocyte, monocyte-to-lymphocyte and platelet-to-lymphocyte ratios in relation to clinical parameters and smoking status in patients with graves’ orbitopathy-novel insight into old tests. J Clin Med 9:3111PubMedPubMedCentral
45.
Forget P, Khalifa C, Defour JP, Latinne D, van Pel MC, de Kock M (2017) What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes 10:12PubMedPubMedCentral
46.
Güden M, Karaman ST, Basat O (2022) Evaluation of the relationship between the level of addiction and exhaled carbon monoxide levels with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in smokers. Tob Induc Dis 20:52PubMedPubMedCentral
47.
Delanian S, Lefaix JL (2004) The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 73:119–131PubMed
48.
Dekker H, Bravenboer N, van Dijk D, Bloemena E, Rietveld DHF, Ten Bruggenkate CM et al (2018) The irradiated human mandible: a quantitative study on bone vascularity. Oral Oncol 87:126–130PubMed
49.
Rankow RM, Weissman B (1971) Osteoradionecrosis of the mandible. Ann Otol Rhinol Laryngol 80:603–611PubMed
50.
Castillo-Rodríguez RA, Trejo-Solís C, Cabrera-Cano A, Gómez-Manzo S, Dávila-Borja VM (2022) Hypoxia as a modulator of inflammation and immune response in cancer. Cancers (Basel) 14:2291PubMed
51.
Reher P, Doan N, Bradnock B, Meghji S, Harris M (1999) Effect of ultrasound on the production of IL‑8, basic FGF and VEGF. Cytokine 11:416–423PubMed
52.
Breen EC (2007) VEGF in biological control. J Cell Biochem 102:1358–1367PubMed
53.
Su L, Zhang M, Zhang W, Cai C, Hong J (2017) Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 96(11):e6364PubMed
54.
55.
Gu C, Wu L, Li X (2013) IL-17 family: cytokines, receptors and signaling. Cytokine 64:477–485PubMed
Metadaten
Titel
Utility of pre-chemoradiotherapy Pan-Immune-Inflammation-Value for predicting the osteoradionecrosis rates in locally advanced nasopharyngeal cancers
verfasst von
Busra Yilmaz
Efsun Somay
Erkan Topkan
Ahmet Kucuk
Berrin Pehlivan
Ugur Selek
Publikationsdatum
11.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 10/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-023-02119-0

Weitere Artikel der Ausgabe 10/2023

Abnormal visual and olfactory sensations during radiation therapy: a prospective study

  • Open Access
  • Original Article

Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer

  • Open Access
  • Original Article

Irradiation dose to the swallowing apparatus impacts nutritional status in head and neck cancer patients—results from the prospective randomized HEADNUT trial

  • Open Access
  • Original Article

The evolving role of reduced-dose total skin electron beam therapy in skin malignancies: the renaissance of a rare indication

  • Open Access
  • Short Communication

Risk assessment, surveillance, and nonpharmaceutical prevention of acute radiation dermatitis: results of a multicentric survey among the German-speaking radiation oncology community

  • Open Access
  • Original Article

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC

  • Open Access
  • NSCLC
  • Kommentierte Studie

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise